The SABR trial and mouse ILDR experiments

The SABR trial (NCT02992912): Patients with advanced colorectal cancer (CRC), renal cell carcinoma, non-small cell lung carcinoma (NSCLC) and sarcomas were enrolled in an phase 2 trial. Atezolizumab (anti-PD-L1 Ab) was delivered in combination with concurrent SABR (recommended dose of 45Gy in 3 fractions,) at the 2nd cycle of atezolizumab. Translational analyses were performed in the context of ONCOBIOTICS study in Gustave Roussy (NCT04567446). Thirty-two participants were enrolled in the translational part of this study. Serum samples were collected from these patients at baseline (V1), before the 2nd cycle of αPD-L1 (V2), after SABR (V3) or at 6 months since the 1st cycle of αPD-L1 (V4) and subjected to targeted metabolomic analysis. The relative abundance of metabolites was correlated with patients survival (OS12 and OS24).

The mouse ILDR experiments: MC38 bearing C57BL/6J mice were subjected to intraperitoneal (i.p.) injections of αPD-L1 Ab with or without 1Gy intestinal low-dose irradiation (ILDR). Plasma samples were collected from these mice at 3 days after ILDR and subjected to targeted metabolomic analysis.